Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, plus fulvestrant with or without palbociclib for second-line treatment of patients with HR+/HER2-/ PIK3CA-WT advanced breast cancer: updated results from the randomized, phase 3 VIKTORIA-1 trial